|
Fusion gene ID: 717 |
FusionGeneSummary for ADAM9_RGS20 |
Fusion gene summary |
Fusion gene information | Fusion gene name: ADAM9_RGS20 | Fusion gene ID: 717 | Hgene | Tgene | Gene symbol | ADAM9 | RGS20 | Gene ID | 8754 | 8601 |
Gene name | ADAM metallopeptidase domain 9 | regulator of G protein signaling 20 | |
Synonyms | CORD9|MCMP|MDC9|Mltng | RGSZ1|ZGAP1|g(z)GAP|gz-GAP | |
Cytomap | 8p11.22 | 8q11.23 | |
Type of gene | protein-coding | protein-coding | |
Description | disintegrin and metalloproteinase domain-containing protein 9ADAM metallopeptidase domain 9 (meltrin gamma)cellular disintegrin-related proteincone rod dystrophy 9metalloprotease/disintegrin/cysteine-rich protein 9myeloma cell metalloproteinase | regulator of G-protein signaling 20gz-selective GTPase-activating proteinregulator of G-protein signaling 20 variant 2regulator of G-protein signaling Z1regulator of G-protein signalling 20regulator of Gz-selective protein signaling 1 | |
Modification date | 20180519 | 20180522 | |
UniProtAcc | Q13443 | O76081 | |
Ensembl transtripts involved in fusion gene | ENST00000487273, ENST00000466936, ENST00000481513, ENST00000484143, | ENST00000297313, ENST00000344277, ENST00000522225, ENST00000276500, ENST00000517405, | |
Fusion gene scores | * DoF score | 13 X 7 X 9=819 | 5 X 4 X 4=80 |
# samples | 14 | 6 | |
** MAII score | log2(14/819*10)=-2.54843662469604 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/80*10)=-0.415037499278844 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ADAM9 [Title/Abstract] AND RGS20 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ADAM9 | GO:0000186 | activation of MAPKK activity | 17704059 |
Hgene | ADAM9 | GO:0006509 | membrane protein ectodomain proteolysis | 9920899 |
Hgene | ADAM9 | GO:0034612 | response to tumor necrosis factor | 11831872 |
Hgene | ADAM9 | GO:0050714 | positive regulation of protein secretion | 17704059 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | RV | PRAD | TCGA-EJ-5510-01A | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000487273 | ENST00000297313 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000487273 | ENST00000344277 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000487273 | ENST00000522225 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000487273 | ENST00000276500 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000487273 | ENST00000517405 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
Frame-shift | ENST00000466936 | ENST00000297313 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000466936 | ENST00000344277 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000466936 | ENST00000522225 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000466936 | ENST00000276500 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000466936 | ENST00000517405 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
Frame-shift | ENST00000481513 | ENST00000297313 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000481513 | ENST00000344277 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000481513 | ENST00000522225 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000481513 | ENST00000276500 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
5CDS-intron | ENST00000481513 | ENST00000517405 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
intron-3CDS | ENST00000484143 | ENST00000297313 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
intron-intron | ENST00000484143 | ENST00000344277 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
intron-intron | ENST00000484143 | ENST00000522225 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
intron-intron | ENST00000484143 | ENST00000276500 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
intron-intron | ENST00000484143 | ENST00000517405 | ADAM9 | chr8 | 38854679 | + | RGS20 | chr8 | 54791818 | + |
Top |
FusionProtFeatures for ADAM9_RGS20 |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ADAM9 | RGS20 |
Cleaves and releases a number of molecules withimportant roles in tumorigenesis and angiogenesis, such as TEK,KDR, EPHB4, CD40, VCAM1 and CDH5. May mediate cell-cell, cell-matrix interactions and regulate the motility of cells viainteractions with integrins. {ECO:0000250|UniProtKB:Q61072}. Isoform 2: May act as alpha-secretase for amyloidprecursor protein (APP). {ECO:0000269|PubMed:12054541}. | Inhibits signal transduction by increasing the GTPaseactivity of G protein alpha subunits thereby driving them intotheir inactive GDP-bound form. Binds selectively to G(z)-alpha andG(alpha)-i2 subunits, accelerates their GTPase activity andregulates their signaling activities. The G(z)-alpha activity isinhibited by the phosphorylation and palmitoylation of the G-protein. Negatively regulates mu-opioid receptor-mediatedactivation of the G-proteins (By similarity). {ECO:0000250,ECO:0000269|PubMed:12379657}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ADAM9_RGS20 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ADAM9_RGS20 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
ADAM9 | MAD2L2, SH3GL2, SNX9, PRKCD, CDH1, RNF2, CD1B, FIGF, TMEM25, PTPRK, GPHA2, CLPSL1, NUDC, KIF2C, ITGAV, ITGB5, SCGB1D4, ADAM32, LYZL2, INSL5, SLAMF1, LYZL1 | RGS20 | OSTM1, NSF, GLRX3, PMVK, SPTLC1, BOLA1, MLF2, SLC39A7, TXLNA, RUVBL2, TRMT112, FAF2, SET, STMN2, GNAZ, GNAO1, ADRB2, KIF1A, FASLG, AQP1, GNAI2, HOXA1, HSPD1, INS, KRTAP5-9, OTX1, PTGER3, CREB5, MAPKBP1, PVRL3, CRCT1, KRTAP4-2, PTPMT1, CATSPER1, TBC1D16, LCE4A, KLHL38, LCE1B, LCE2A, LCE2D, LCE3E, KRTAP5-6, ABHD17A, AARSD1, TTC7B, NARF, CRY1, SELO, EFR3B, FAM126A, NBN, RAD50, ZNF664, RGS19, NARFL, DPH2, TXLNG, EFR3A, MOCOS, MIOS, ZYG11B, MRE11A, KIF3B, TYW1, ZNF696, TRMT1L, ZNF444, GFER, PI4KA, PLK1, KIF3A, DPH1, NLN, PRIM2, ATP6V0A1, CTU2, TARBP1, CIAPIN1, DCAF10, CUL2, PGP |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ADAM9_RGS20 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ADAM9_RGS20 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | ADAM9 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Tgene | RGS20 | C0024809 | Marijuana Abuse | 1 | PSYGENET |